Results from a trial assessing cardiovascular risk with NSAIDs and COX-2 inhibitors are reassuring for rheumatologists and their patients but are unlikely to change clinical practice, an expert says. The Standard care versus Celecoxib Outcome Trial (SCOT) randomised trial of over 7,000 arthritis patients aged over 60 with no history of heart disease found no increased risk of ...
NSAID safety concern eased by SCOT trial
By Nicola Garrett
9 Sep 2015